Selvita is a global integrated drug discovery partner for the pharmaceutical and biotechnology industries with offices in Greater Boston Area and San Francisco Bay Area, US, as well as Cambridge, UK and two research sites in: Krakow and Poznan, Poland.

The company offers drug discovery support at every stage of the early discovery phase up to the preclinical research phase.

Currently Selvita employs over 400 scientists, including 30% with PhD degree and extensive experience in several areas of life sciences, offering the following types of projects:

  • Contract chemistry services: medicinal chemistry, custom organic synthesis, scale-up and process chemistry, as well as industrial chemistry
  • Biology services: cell and molecular biology, ADME and pharmacokinetics, proteomic analyses, analytical chemistry and method validation
  • Comparative studies of biosimilar products
  • Integrated drug discovery projects combining variety of drug discovery processes from in silico drug design, and synthesis of a target-focused library, SAR and ADME-driven lead optimization and toxicity prediction, followed by complex preclinical in vitro development, all tailored to the customer’s needs.


Selvita’s laboratories possess both GLP and GMP certification. Drug discovery clients of Selvita include more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe.

Selvita is listed on the Main Market of Warsaw Stock Exchange (WSE:SLV).